TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Frequency of absence seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Diagnostic validity of the SEFI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 1st time for rescue analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in nomophobia score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Overall Severity Score (Parent Questionnaire)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Overall Severity Score (Teacher Questionnaire)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD115 and CD265 expression on circulating monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average total height of jumps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Force production of jumps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in soleus EMG response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patient adherence rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient tolerability rate
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of treatment regimen to participants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of participants requiring mechanical ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants not surviving to hospital discharge
Endpoint domain: Mortality/survival
Primary endpoint: Aqueous humor concentrations of inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: POC-CNN Model AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outflow facility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of COPD exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient symptomatology according to the modified British Medical Research Council (mMRC) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety of stereotactic ablative radiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: diagnostic accuracy of SEMA4C in predicting recurrence of breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dual-task cost of balance performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proband-reported cascade testing rates of first-degree relatives
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Family member-reported cascade testing rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients without treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear of cancer recurrence (FCR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficiency of aligners in molar distalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fusion Status of 1 level Lumbar TLIF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Revision Surgeries
Endpoint domain: Adverse events/effects
Primary endpoint: Whole-tumor lactate/pyruvate ratio measured with MRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole-tumor glucose uptake measured with PET (static)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole-tumor glucose uptake measured with PET (dynamic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: OCTA macula and ONH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative allogeneic red blood cell transfusion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: change in cardiovascular health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Nijmegen score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: paraspinal muscles cross-section area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean change in sleep bout length
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in sleep rhythmicity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in sleep continuity and duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Nutritional status of patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants achieving full desensitisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recruitment and retention rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Subject's satisfaction with STYLAGE® HYDRO
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in distance walked in 6 minute walk test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel Management Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PedsQLTM Multidimensional Fatigue Scale (PedsQL-MFS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Reduction in sFlt-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eligible individuals agreeing to participate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of participants who are retained through follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of participants who complete the intervention and assessments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participant satisfaction with the project
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intention to vaccinate the children against HPV
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in EEG spectral alpha and beta-band power during movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in beta band after movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: A1c level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in driving airway pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Heart-Rate Variability (time domain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Heart-Rate Variability (frequency domain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Drug screen completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Variation of number of well-being patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean SF-36 Physical Component Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Maximum Cystometric Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Range of motion of shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPADY scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cervical Range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wong-Baker Scale Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent adoption of the program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Urine F2-isoprostane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percent of hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: percent of Death
Endpoint domain: Mortality/survival
Primary endpoint: Level of perimenopausal depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Motor Functional Exercise Compliance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pre-Frail/Frail Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaching Target Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PCL-5 Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Days alive and out of hospital at day 30
Endpoint domain: Mortality/survival
Primary endpoint: Change in Wechsler intelligence scale scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Isometric elbow flexion/extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Active elbow and knee range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Disease knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative incidence of Grade 3 and 4 adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in white blood cell count (CBC) through Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pulse Oximetry Errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of IgG anti-SARS-CoV-2 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in wound area size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days to complete wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of Infective Bacterial Diseases from Streptococcus pneumoniae
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of Infective Bacterial Diseases from Neisseria meningitidis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of Infective Bacterial Diseases from Haemophilus influenzae
Endpoint domain: Adverse events/effects
Primary endpoint: Shear wave speed (SWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of pancreatic cancer
Endpoint domain: Mortality/survival
Primary endpoint: Maximum measured concentration after first dose of denosumab and denosumab-ref
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration versus time curve from time zero to the last measurable concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration versus time curve from time zero to infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in lumbar spine bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Cardiorespiratory Fitness (CRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in risk of mortality
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients with major adverse cardiac and cerebrovascular events (MACCE)
Endpoint domain: Adverse events/effects
Primary endpoint: Visual analog scale (VAS) pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of enrollment in clinical trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients remaining until completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median time to neutrophil cell reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Disfluent syllables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the observed concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the observed maximum concentration [Tmax]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target cell number for dose manufacturing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safe maximum tolerated dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort Behaviors Checklist
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Richard-Campbell Sleep Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Major Complication Rates
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Breast-Q questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: VSS total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of recurrent VTE or any bleed resulting in hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrent VTE (fatal and non-fatal)
Endpoint domain: Adverse events/effects
Primary endpoint: Any bleed resulting in hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Quality of Life Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Function of stoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: JAK/STAT family protein expression in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver Burden Interview
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: RSV-A Neutralization Titers (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: RSV-A Seroresponse Rate (SRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: RSV-B Neutralization Titers (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: RSV-B Seroresponse Rate (SRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAE's)
Endpoint domain: Adverse events/effects
Primary endpoint: cognition crystallized composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of dose limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Postprandial plasma total amino acid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intestinal fractional calcium absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in the concentration of inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the concentration of immunosuppression markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the number of immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity of Detecting MASLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Detecting MASLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Receiver Operating Curve (ROC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Excretion of LY3556050 Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fecal Excretion of LY3556050 Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in International Cooperative Ataxia Rating Scale (ICARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Neck proprioception error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain free weight bearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with platelet response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion subjects with an immune response to romiplostim
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VTE-related composite event
Endpoint domain: Adverse events/effects
Primary endpoint: Seizure-freedom rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean economic stability score
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Pulmonary embolism-related death
Endpoint domain: Mortality/survival
Primary endpoint: Spine surgical patient outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombolysis rate within 4.5 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device survival
Endpoint domain: Mortality/survival
Primary endpoint: Oral functional score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Seroconversion of Hepatitis C Virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Episiotomy wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean intima-media thickness of the common carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum intima-media thickness of the internal carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Carotid plaque burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Magnitude of displacement of the splinted teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat-free Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Modified Physical Performance Test
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of participants achieving pCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Marijuana Craving Questionnaire (MCQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of SNPs associated with bronchial asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of post treatment recoil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum (peak) serum drug concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants reporting unsolicited adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with antigen 1 seroconversion rate (SCR)
Endpoint domain: Physiological/clinical
Primary endpoint: Sensitivity of detecting plasma ctDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GMT of neutralizing antibodies to Delta variant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Eccentric muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Concentric muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: real world progress free survival (rwPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in child health-related quality of life (HR-QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in parent health-related quality of life (HR-QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: left ventricular ejection fraction (EF %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ACE2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prescription rate of ACE/ARNI according to the guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prescription rate of betablockers according to the guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prescription rate of MRA according to the guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prescription rate of SGLT2i according to the guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prescription rate of periodic screening of iron insufficiency
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention